Legato Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Legato Capital Management’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$828K	Buy	87,010 +63,061	+263%	+$490K	0.08%	351
2025 Q4	$187K	Buy	23,949 +2,172	+10%	+$15.7K	0.02%	717
2025 Q3	$165K	Hold	21,777	–	–	0.02%	523
2025 Q2	$195K	Sell	21,777 -345	-2%	-$3.21K	0.02%	521
2025 Q1	$166K	Sell	22,122 -1,471	-6%	-$11.9K	0.02%	522
2024 Q4	$177K	Hold	23,593	–	–	0.02%	528
2024 Q3	$179K	Hold	23,593	–	–	0.02%	526
2024 Q2	$146K	Buy	23,593 +368	+2%	+$2.03K	0.02%	529
2024 Q1	$118K	Hold	23,225	–	–	0.01%	543
2023 Q4	$139K	Hold	23,225	–	–	0.02%	541
2023 Q3	$164K	Buy	+23,225	New	+$167K	0.02%	518

Other funds holding BCRX

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Janus Henderson Group

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors New York $5.06B AUM 314.02% 1-Year Est. Return

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return